PTPRC and neoplasm: Furthermore, cilengitide, WP1066, or AR-A014418 treatment increased activated CD4+ (CD45+CD3+CD8–CD4+CD69+) and CD8+ T cells (CD45+CD3+CD8+CD4–CD69+), and these effects were improved when CT2A tumor–bearing mice received the treatment with cilengitide combined with WP1066 or AR-A014418 (Supplemental Figure 9, E and F).